doxypep

Episode 9 - Understanding The Implementation of Doxycycline Post-Exposure Prophylaxis (DoxyPEP) and Addressing Sexually Transmitted Infections with Dr Annie Luetkemeyer

In this episode of Going anti-Viral, Dr Michael Saag has an insightful discussion with Dr Annie Luetkemeyer, a professor of medicine in the Division of HIV, Infectious Diseases, and Global Medicine at Zuckerberg San Francisco General at the University of California San Francisco.  Centering around the state of sexually transmitted infections in the United States, rising cases, strategies for control, and the promising role of doxycycline post-exposure prophylaxis (DoxyPEP)

00:02 Introduction to the Podcast

01:31 Discussion on the State of Sexually Transmitted Infections

05:21 Exploring the Concept of Post-Exposure Prophylaxis

07:19 Understanding the Implementation of DoxyPEP

10:23 Effectiveness of DoxyPEP

17:41 Potential Side Effects and Concerns of DoxyPEP

22:37 Future Prospects of DoxyPEP in STI Prevention

28:04 Conclusion and Final Thoughts

28:46 Podcast Closing Remarks

__________________________________________________

Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.

Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...

In this episode, Aniruddha (Anu) Hazra, MD, and Ofole Mgbako, MD, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: 

• Data on drug–drug interactions between PrEP options and gender-affirming hormone therapy
• Contributing factors to inequities in PrEP uptake for Black and Latino individuals
• Data on FTC/TAF PrEP for transgender individuals
• How to decide whether to do an oral lead-in before starting injectable cabotegravir PrEP
• Time to effectiveness after starting PrEP 
• PrEP resources available for transgender communities, especially regarding stigma
• Integration of PrEP with gender-affirming hormone therapy
• Strategies to increase PrEP uptake, specifically in the south
• Counseling patients on drug–drug interactions, adverse events, and transmission risk when starting PrEP
• Involving PrEP navigators in the care of people receiving PrEP
• Supporting PrEP adherence and retention in care
• The use of DoxyPEP in transgender individuals receiving PrEP

Faculty

Aniruddha (Anu) Hazra, MD
Assistant Professor, Section of Infectious Disease and Global Health
Director, Infectious Diseases Fellowship Program
Medical Director, UCM Sexual Wellness Clinic
Director of STI Services, Chicago Center of HIV Elimination
Department of Medicine
University of Chicago
Chicago, Illinois

Ofole Mgbako, MD
Assistant Professor of Medicine and Population Health  
Section Chief of Infectious Disease
Bellevue Hospital
Clinical Pillar Lead, NYU Institute for Excellence in Health Equity
NYU Grossman School of Medicine
NYU Langone Health
New York, New York

Link to full program: https://bit.ly/3PZGYdR

In this episode, Raphael J. Landovitz, MD, MSc, and Hyman Scott, MD, MPH, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: 

• Misconceptions about PrEP eligibility 
• Strategies to improve lab monitoring on PrEP 
• Leveraging patient navigators and clinic staff to expand PrEP access
• Data on PrEP efficacy in key populations (eg, transgender men, people who inject drugs)
• Considerations for prescribing on-demand and same-day PrEP 
• Addressing healthcare professional hesitancy to prescribe PrEP
• US Preventive Services Task Force PrEP guideline updates
• Bundling sexually transmitted infection services with PrEP

Faculty

Raphael J. Landovitz, MD, MSc
Professor of Medicine
Division of Infectious Diseases
David Geffen School of Medicine
University of California, Los Angeles
Director, UCLA Center for Clinical AIDS Co-Director, Center for HIV Identification, Prevention, and Treatment Services 
Los Angeles, California

Hyman Scott, MD
Assistant Clinical Professor
Department of Medicine
University of California, San Francisco
Clinical Research Medical Director
Bridge HIV
San Francisco Department of 
Public Health
San Francisco, California

Link to full program: 
https://bit.ly/3PZGYdR

In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses new HIV data from AIDS 2022, including:

• Prevention strategies
• Oral therapies
• LA therapies
• Cure
• COVID-19 in PWH

Faculty
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Follow along with the slides at
bit.ly/3SLuhBq